Discounted Cash Flow
Viemed Healthcare, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2018 | $64.5m | $9.5m | $16.3m | 14.7% | $0.26 |
| 2019 | $80.3m (24.5%) | $8.5m (-10.3%) | $5.7m (-64.9%) | 10.6% (-28.0%) | $0.23 (-8.6%) |
| 2020 | $131.3m (63.6%) | $31.5m (269.9%) | $22.1m (287.0%) | 24.0% (126.1%) | $0.68 (191.8%) |
| 2021 | $117.1m (-10.8%) | $9.1m (-71.1%) | $2.8m (-87.5%) | 7.8% (-67.5%) | $0.32 (-53.5%) |
| 2022 | $138.8m (18.6%) | $6.2m (-31.8%) | $4.8m (76.3%) | 4.5% (-42.5%) | $0.23 (-26.5%) |
| 2023 | $183.0m (31.8%) | $10.2m (64.6%) | $19.1m (294.2%) | 5.6% (24.9%) | $0.38 (61.3%) |
| 2024 | $224.3m (22.5%) | $11.3m (10.0%) | $1.3m (-93.1%) | 5.0% (-10.3%) | $0.42 (11.2%) |
| 2025 | $270.3m (20.5%) | $14.9m (32.6%) | $11.9m (805.2%) | 5.5% (10.0%) | $0.56 (34.1%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.